Registry of gastric cancer treatment evaluation (<scp>REGATE</scp>): <scp>II</scp> treatment practice

Тер-Ованесов, М. Д.; Yalçın, Şuayib; Zalcberg, John; Hitier, Simon; Bang, Yung Jue; Wu, Chew Wun; Roth, Arnaud

doi:10.1111/ajco.12089

Cited by 11 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found variations in treatment patterns in both first- and second-line treatment regimens of patients with MGC. These findings are consistent with the results reported for a REGATE study in which 96% of patients received adjuvant chemotherapy consisting of varying agents, combinations and routes of administration [4]. Recently published guidelines for the diagnosis and treatment of gastric cancer in Korea [8] recommend fluoropyrimidines, platinums, taxanes, irinotecan, and anthracyclines as first-line chemotherapy and state no standard for second-line has been established, while these guidelines were published prior to recent approvals the second line [9-11].…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea

et al. 2017

Self Cite

View full text Add to dashboard Cite

PurposeThe purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/or locally recurrent, unresectable gastric cancer (MGC) in South Korea.Materials and MethodsThirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. Kaplan-Meier analysis was used to describe survival.ResultsOf 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current or former smokers. The majority of tumorswere located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity indexwas 0.4 (standard deviation, 0.6). The most common comorbidities were chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second-line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients.ConclusionMost patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.

show abstract

Section: Discussionsupporting

confidence: 92%

“…There is also limited information available on gastric cancer patient characteristics, healthcare resource use and treatment patterns [1,2,4]. …”

Section: Introductionmentioning

confidence: 99%

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…We found variations in treatment patterns in both first-and second-line treatment regimens of patients with MGC. These findings are consistent with the results reported for a REGATE study in which 96% of patients received adjuvant chemotherapy consisting of varying agents, combinations and routes of administration [4]. Recently published guidelines for the diagnosis and treatment of gastric cancer in Korea [8] recommend fluoropyrimidines, platinums, taxanes, irinotecan, and anthracyclines as first-line chemotherapy and state no standard for second-line has been established, while these guidelines were published prior to recent approvals the second line [9][10][11].…”

Section: Discussionsupporting

confidence: 84%

“…There is also limited information available on gastric cancer patient characteristics, healthcare resource use and treatment patterns [1,2,4]. Therefore, this study was conducted to understand treatment patterns, patient outcomes, and healthcare resource use in South Korean patients with metastatic and/or locally recurrent, unresectable gastric cancer (MGC), including cancer of the stomach and gastroesophageal junction with adenocarcinoma histology.…”

Section: Introductionmentioning

confidence: 99%

Real-world treatment patterns among patients with advanced gastric cancer in South Korea.

Carter¹,

Kaltenboeck²,

Ivanova³

et al. 2014

JCO

Self Cite

View full text Add to dashboard Cite

Original ArticlePurpose The purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/or locally recurrent, unresectable gastric cancer (MGC) in South Korea. Materials and MethodsThirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. KaplanMeier analysis was used to describe survival. ResultsOf 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current or former smokers. The majority of tumors were located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity index was 0.4 (standard deviation, 0.6). The most common comorbidities were chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second-line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients. ConclusionMost patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.

show abstract

“…This manuscript reports the baseline demographic and disease characteristics and overall treatment plans of patients enrolled in the REGATE registry. The accompanying article describes approaches to the treatment of gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics

Bang

Yalçın

Roth

et al. 2013

Asia-Pac J Clncl Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Registry of gastric cancer treatment evaluation (REGATE): II treatment practice

Abstract: These data showing geographical differences in the approaches to gastric cancer treatment may promote the optimization of the management of gastric cancer globally.

Cited by 11 publications

References 7 publications

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea

Real-world treatment patterns among patients with advanced gastric cancer in South Korea.

Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics

Contact Info

Product

Resources

About